Healthcare provider profile · identity verified

Abdulateef Olasunkanmi Aregbe, M.D

Hospitalist · FISHERS, IN · NPI 1972756245

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	753	58
Amlodipine Besylate	Amlodipine Besylate	473	39
Potassium Chloride	Potassium Chloride	427	35
Pantoprazole Sodium	Pantoprazole Sodium	405	36
Furosemide	Furosemide	393	39
Tamsulosin Hcl	Tamsulosin Hcl	380	24
Gabapentin	Gabapentin	310	30
Levothyroxine Sodium	Levothyroxine Sodium	302	22
Eliquis	Apixaban	296	26
Losartan Potassium	Losartan Potassium	280	24
Metoprolol Succinate	Metoprolol Succinate	265	21
Lisinopril	Lisinopril	258	21
Trazodone Hcl	Trazodone Hcl	255	20
Quetiapine Fumarate	Quetiapine Fumarate	232	16
Levetiracetam	Levetiracetam	229	14
Clopidogrel	Clopidogrel Bisulfate	224	18
Allopurinol	Allopurinol	179	suppressed
Carvedilol	Carvedilol	166	18
Rosuvastatin Calcium	Rosuvastatin Calcium	127	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	125	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	118	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	115	22
Torsemide	Torsemide	112	13
Memantine Hcl	Memantine Hcl	110	suppressed
Simvastatin	Simvastatin	108	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	104	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	103	11
Sertraline Hcl	Sertraline Hcl	93	16
Valsartan	Valsartan	85	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	83	suppressed
Fenofibrate	Fenofibrate,micronized	78	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	78	19
Rivastigmine	Rivastigmine Tartrate	78	suppressed
Jardiance	Empagliflozin	74	suppressed
Metformin Hcl	Metformin Hcl	72	suppressed
Duloxetine Hcl	Duloxetine Hcl	70	suppressed
Hydralazine Hcl	Hydralazine Hcl	66	11
Midodrine Hcl	Midodrine Hcl	66	suppressed
Baclofen	Baclofen	62	suppressed
Bupropion Xl	Bupropion Hcl	55	suppressed
Humalog	Insulin Lispro	54	suppressed
Buspirone Hcl	Buspirone Hcl	52	suppressed
Donepezil Hcl	Donepezil Hcl	52	suppressed
Chlorthalidone	Chlorthalidone	50	suppressed
Divalproex Sodium	Divalproex Sodium	49	suppressed
Lamotrigine	Lamotrigine	49	suppressed
Verapamil Er	Verapamil Hcl	49	suppressed
Mirtazapine	Mirtazapine	46	11
Lovastatin	Lovastatin	45	suppressed
Prednisone	Prednisone	44	suppressed
Risperidone	Risperidone	44	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	43	suppressed
Omeprazole	Omeprazole	43	suppressed
Enoxaparin Sodium	Enoxaparin Sodium	41	suppressed
Spironolactone	Spironolactone	41	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	40	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	40	26
Humalog Kwikpen U-100	Insulin Lispro	39	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	39	suppressed
Montelukast Sodium	Montelukast Sodium	38	suppressed
Ramelteon	Ramelteon	38	suppressed
Nuedexta	Dextromethorphan Hbr/Quinidine	37	suppressed
Ondansetron Hcl	Ondansetron Hcl	37	18
Cephalexin	Cephalexin	35	12
Citalopram Hbr	Citalopram Hydrobromide	34	suppressed
Flecainide Acetate	Flecainide Acetate	32	suppressed
Glimepiride	Glimepiride	32	suppressed
Diltiazem 24hr Er (La)	Diltiazem Hcl	30	suppressed
Pravastatin Sodium	Pravastatin Sodium	29	suppressed
Valacyclovir	Valacyclovir Hcl	29	suppressed
Finasteride	Finasteride	27	suppressed
Ropinirole Hcl	Ropinirole Hcl	27	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	25	suppressed
Divalproex Sodium Er	Divalproex Sodium	25	suppressed
Metformin Hcl Er	Metformin Hcl	25	suppressed
Tradjenta	Linagliptin	25	suppressed
Bethanechol Chloride	Bethanechol Chloride	24	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	24	suppressed
Doxepin Hcl	Doxepin Hcl	23	suppressed
Famotidine	Famotidine	23	suppressed
Alendronate Sodium	Alendronate Sodium	22	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	22	11
Albuterol Sulfate Hfa	Albuterol Sulfate	21	11
Clonidine Hcl	Clonidine Hcl	21	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	21	suppressed
Myrbetriq	Mirabegron	20	suppressed
Lidocaine	Lidocaine	19	suppressed
Naproxen	Naproxen	19	suppressed
Propranolol Hcl	Propranolol Hcl	19	suppressed
Xifaxan	Rifaximin	19	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	18	suppressed
Fluticasone Propionate	Fluticasone Propionate	18	11
Naltrexone Hcl	Naltrexone Hcl	17	suppressed
Dorzolamide-Timolol	Dorzolamide Hcl/Timolol Maleat	16	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	16	suppressed
Aripiprazole	Aripiprazole	15	suppressed
Breo Ellipta	Fluticasone/Vilanterol	15	suppressed
Xarelto	Rivaroxaban	15	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	14	11
Diclofenac Sodium	Diclofenac Sodium	14	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	14	suppressed
Linzess	Linaclotide	14	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	14	suppressed
Primidone	Primidone	14	suppressed
Atenolol	Atenolol	13	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	13	suppressed
Pentoxifylline	Pentoxifylline	13	suppressed
Bupropion Hcl Sr	Bupropion Hcl	12	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	12	suppressed
Latanoprost	Latanoprost	12	suppressed
Nystop	Nystatin	12	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	12	suppressed
Phenytek	Phenytoin Sodium Extended	12	suppressed
Topiramate	Topiramate	12	suppressed
Colestipol Hcl	Colestipol Hcl	11	suppressed
Incruse Ellipta	Umeclidinium Bromide	11	suppressed
Lubiprostone	Lubiprostone	11	suppressed
Methocarbamol	Methocarbamol	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error